An experimental Alzheimer's drug, diranersen, has shown promise in slowing cognitive decline by targeting the tau protein, a different approach than current amyloid-focused treatments. While the drug did not meet all its primary study goals, results presented at a conference indicated a significant reduction in cognitive decline for some participants, comparable to existing therapies. Researchers are optimistic about this novel mechanism and are planning larger studies, though they caution that it is still early days for this potential treatment. AI
IMPACT This development could spur further research and investment into novel therapeutic mechanisms for neurodegenerative diseases.
RANK_REASON The item reports on results from a study of an experimental drug presented at a conference, indicating potential for a new treatment approach for a disease. [lever_c_demoted from research: ic=1 ai=0.1]
- Alzheimer's disease
- amyloid
- Biogen
- Cath Mummery
- diranersen
- donanemab
- Ionis Pharmaceuticals
- lecanemab
- London
- Mass General Brigham
- Phoenix
- Reisa Sperling
- University College London
AI-generated summary · Google Gemini · from 1 sources. How we write summaries →
